SCHEMBL3362480

SCHEMBL3362480

O=C1NC(=O)/C(=C/c2ccc(-c3ccc(C(=O)O)cc3)o2)N1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3A P49840 3/20 0.77
GSK3B P49841 3/20 0.77
INSR P06213 1/20 0.61
IGF1R P08069 1/20 0.61
CDK2 P24941 1/20 0.60
TDP1 Q9NUW8 4/20 0.57
KDM4E B2RXH2 3/20 0.57
MAPT P10636 3/20 0.55
L3MBTL1 Q9Y468 3/20 0.55
APEX1 P27695 2/20 0.55
ALDH1A1 P00352 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
MEN1 O00255 4/20 0.54
KMT2A Q03164 4/20 0.54
GFER P55789 2/20 0.54
LMNA P02545 1/20 0.54
RECQL P46063 1/20 0.54
MCL1 Q07820 1/20 0.54
POLB P06746 1/20 0.54
DNMT1 P26358 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3362481 1.00 GSK3A (0.77) GSK3AGSK3BINSRIGF1RCDK2
SCHEMBL12990390 1.00 GSK3A (0.77) GSK3AGSK3BINSRIGF1RCDK2
SCHEMBL5146624 0.88 MEN1 (0.69) GSK3AGSK3BINSRIGF1RCDK2
SCHEMBL3365349 0.85 GSK3A (0.79) GSK3AGSK3BTDP1KDM4EMAPT
SCHEMBL12990771 0.85 GSK3A (0.79) GSK3AGSK3BTDP1KDM4EMAPT
SCHEMBL3365346 0.85 GSK3A (0.79) GSK3AGSK3BTDP1KDM4EMAPT
SCHEMBL5143410 0.81 PPM1G (0.62) GSK3AGSK3BTDP1KDM4EMAPT
SCHEMBL5143032 0.81 POLB (0.65) GSK3AGSK3BTDP1KDM4EMAPT
SCHEMBL5143034 0.81 POLB (0.65) GSK3AGSK3BTDP1KDM4EMAPT
SCHEMBL5143408 0.81 PPM1G (0.62) GSK3AGSK3BTDP1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100331315-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS SENHWA BIOSCIENCES, INC. (TW) 2010-12-30 US disclosed
US-20100331315-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS SENHWA BIOSCIENCES, INC. (TW) 2010-12-30 US disclosed
US-20100331315-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS SENHWA BIOSCIENCES, INC. (TW) 2010-12-30 US disclosed
WO-2010148351-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS CYLENE PHARMACEUTICALS, INC. (US) 2010-12-23 WO disclosed
WO-2010148351-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS CYLENE PHARMACEUTICALS, INC. (US) 2010-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331315-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS PIM2, PIM1, CDK2 GSK3A 412/4885GSK3B 375/4885INSR 1642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.